Penn Davis Mcfarland Inc Reata Pharmaceuticals Inc Transaction History

Penn Davis Mcfarland Inc

  • $849 Million
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 21, 2023
BUY
$30.85 - $93.17 $79,130 - $238,981
2,565 New
2,565 $233,000
Q4 2021

Jan 20, 2022
SELL
$25.61 - $110.96 $65,689 - $284,612
-2,565 Closed
0 $0
Q1 2021

Apr 21, 2021
SELL
$94.25 - $132.81 $120,922 - $170,395
-1,283 Reduced 33.34%
2,565 $256,000
Q1 2020

Apr 20, 2020
SELL
$124.16 - $247.74 $159,297 - $317,850
-1,283 Reduced 25.0%
3,848 $555,000
Q4 2019

Jan 17, 2020
BUY
$74.57 - $217.92 $382,618 - $1.12 Million
5,131 New
5,131 $1.05 Million

Others Institutions Holding RETA

# of Institutions
5
Shares Held
62.7K
Call Options Held
0
Put Options Held
0
View Full List

About REATA PHARMACEUTICALS INC

RETA Quotes by TradingView
  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track This Portfolio

Track Penn Davis Mcfarland Inc Portfolio

Follow Penn Davis Mcfarland Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Penn Davis Mcfarland Inc, based on Form 13F filings with the SEC.

News

Stay updated on Penn Davis Mcfarland Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email